fda semaglutide compounding enforcement november 2025 Drug compounders sue over declaration ending Wegovy shortage Important Notice: Tirzepatide Compounding Update

Her research focuses on the evaluation of clinical and economic value of GLP-1 receptor agonists in obesity treatment, aiming to inform healthcare policy and coverage decisions

The broad, shortage-based compounding pathway ended after the FDA resolved the semaglutide and tirzepatide shortages, and in April 2026 the FDA proposed excluding these drugs from the 503B outsourcing-facility bulks list, with a comment period through June 29, 2026

Prescription & Pharmacy Fulfillment If approved, IVY RX issues a prescription that is fulfilled by a partner pharmacyoften a compounding pharmacy for semaglutide or tirzepatide

Oral formulations command a higher price point due to manufacturing complexity and absorption considerations

For branded medication, Amazon Pharmacy dispenses the oral Wegovy pill from $149 a month at the starter dose, the cheapest branded cash path tracked